Implicity secures $40M growth equity funding to scale its AI-driven cardiac monitoring platform globally

• The round is led by growth fund IRIS alongside Five Arrows.
• Funding will fuel Implicity’s next phase of growth in the US through local commercial hires, build on its established leadership across Europe, and accelerate further AI investment.
• Implicity already serves over 250 medical centers and monitors 120,000+ patients daily across the US, France, and Germany.

CAMBRIDGE, Mass. and PARIS, Sept. 09, 2026 (GLOBE NEWSWIRE) — Implicity, a global leader in AI-driven cardiac remote monitoring, has secured a $40 million funding round led by European tech growth capital firm IRIS, alongside Five Arrows, the alternative assets arm of Rothschild & Co.

Enabling clinicians to act on cardiac data at scale

Remote patient monitoring has become the standard of care in cardiology following the 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus¹. Today, care teams manage more sources than ever, from cardiac implantable electronic devices to heart failure monitoring. While each new data stream provides valuable clinical insight, it also adds complexity for the clinicians piecing the full picture together. Too much time is spent navigating multiple systems and triaging alerts to identify events that require action. This administrative burden reduces time available for direct patient care, potentially delaying responses to the events that matter most.

Implicity helps to solve this with a single, AI-driven platform that aggregates, normalizes, and analyzes data across the full continuum, regardless of device manufacturer. It also integrates with EHRs to streamline providers’ workflow. By bringing every signal into one intelligent view, Implicity lets clinicians spend less time searching through the noise and more time on patient care.

“I didn’t become a physician to manage data — I became one to treat patients,” said Dr. Arnaud Rosier, electrophysiologist, CEO and co-founder of Implicity. “This funding lets us care for patients at scale, catching the information through the noise to provide the best possible care — and that’s the future of cardiology I’ve been chasing since my first year as an electrophysiologist.”

Proven clinical impact and market traction

Unlike traditional remote monitoring solutions, Implicity has built deep clinical credibility through its FDA-cleared AI algorithms and extensive real-world evidence. Patients monitored with Implicity have seen 26% reduction in mortality and 4% reduction in hospitalizations,² compared to those on conventional remote monitoring. SignalHF^†, Implicity’s heart failure prediction algorithm, gives clinicians early visibility into a patient’s heart failure risk to support earlier identification and intervention.³ The platform’s ECG Analyzer^‡ feature also reduces false alarms by up to 76%,^4,5 so clinicians spend less time sorting through alerts and more time with the patients who need them most.

The fundraising will support Implicity’s next phase of growth in the US. The company has built its hospital network on the ground from its Cambridge, MA base, earning the endorsement of clinicians and forging partnerships with local physicians. The round will be used for commercial hiring to widen that footprint and the development of US-specific features for one of the world’s largest healthcare markets. It will also fund continued investment in the company’s AI and innovation roadmap — including the next generation of Heart Failure prediction algorithms — to better serve medical teams and optimize care for remotely monitored patients.

Nicolas Herschtel, Partner at IRIS’ Growth team, added, “In the evolving healthtech landscape, long-term success requires a rare combination of robust technology, strict regulatory clearance, and undeniable clinical utility. Implicity has proven to be a highly trusted partner to complex health systems because its platform directly addresses the administrative and operational crisis facing hospital workforces today. We are thrilled to back the team as they cement their leadership in the US market and drive the next phase of digital healthcare infrastructure.”

François-Xavier Lehman, Director at Five Arrows, commented, “Implicity is a rare company where clinical superiority, regulatory credibility and genuine patient impact come together at scale. By turning fragmented cardiac data into action, it improves outcomes for patients while relieving the operational pressure on hospital teams. This is precisely the kind of sustainable, mission-driven business we seek to support.”

About Implicity

Implicity is a digital medtech company specializing in cardiac remote monitoring. Its platform embeds proprietary algorithms, certified as medical devices, that improve clinical efficiency and predictive accuracy. The company’s independent, universal platform monitors patients with cardiac implantable electronic devices (CIEDs) and heart failure, turning their data into actionable insights for cardiologists and medical teams. Implicity supports medical teams across Europe and the United States in delivering more efficient, predictive, and proactive cardiac care.

About IRIS

IRIS is a European Growth and Venture capital equity firm specialized in tech, investing in seed, Series A, late stage, and growth. With offices and teams in Berlin, Munich and Paris, and a keen understanding of their markets and a robust international network, IRIS is a selective partner to the upcoming scale-ups and tech giants, helping them increase their visibility, business reach, and impact across the world. IRIS investments include, among others, Adjust, Braincube, Escape, Exotec, Kyriba, Jedox, LeanIX, LumApps, Open-Xchange, pyck, Red Points, Shift Technology, Spinergie, SurePay, Talend, Talon.one and Zeta Global. For more information, visit www.iris.vc

About Five Arrows

Five Arrows is the alternative assets arm of Rothschild & Co and has more than €34 billion in assets under management, with offices in Paris, London, New York, Los Angeles, San Francisco, and Luxembourg.

This investment was made through the Five Arrows Sustainable Investments (FASI) fund, a direct minorities SFDR Article 9 fund.

For more information, please visit: https://www.rothschildandco.com/en/five-arrows/multi-strategies/fasi/

† – SignalHF is an FDA-cleared Class II medical device, see the instructions for use for more information.

‡ – IM007 ILR ECG Analyzer is an FDA-cleared Class II medical device, see the instructions for use for more information.

1 – Ferrick AM, Raj SR, Deneke T, et al. “2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic.” Heart Rhythm. 2023;20(9):e92-e144. doi:10.1016/j.hrthm.2023.03.1525.

2 – Varma N, Marijon E, Vicaut É, et al. Impact of a universal monitoring system (“third party”) on outcomes of ICD patients: A nationwide study. Heart Rhythm. 2025;22(10):2661-2668. doi:10.1016/j.hrthm.2024.11.029.

3 – Varma N, Boveda S, Ibnouhsein I, Faedda G, Rosier A, Singh J. Heart failure events prediction algorithm for patients implanted with multi-brand CIED. Europace. 2024;26(Suppl 1):euae102.553. doi:10.1093/europace/euae102.553.

4 – Varma N, Wadhwa M, Lazarus A, Faedda G, Mabo P, Crespin E. Performance of a cloud-based AI solution for reducing false positive alerts in implantable cardiac monitors detected episodes. Europace. 2026;28(Suppl 1):euag105.043. doi:10.1093/europace/euag105.043.

5 – Marijon E, Crespin E, Leclercq C, Faedda G, Mabo P, Barraud J, Varma N. PO-01-235: Performance of a new cloud-based AI solution reducing false positive alerts in implantable cardiac monitor episodes on top of manufacturer AI algorithms. Heart Rhythm. 2026;23(4 Suppl):S294-S295. doi:10.1016/j.hrthm.2026.03.1775.

IMPLICITY®, Inc., a Delaware corporation with offices located at 185 Alewife Brook Pkwy 210, Cambridge, MA 02138 USA, file number 5917973.

Media Contacts:

Samantha Choinski 
samantha@emediajunction.com